MedTrace Logo

The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases

NCT00607217 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2009-01-22

No results posted yet for this study

Summary

This study wishes to understand:

1. whether vaccination against influenza in coronary artery disease (myocardial infarction and stable angina) patients is as effective as it is in healthy subjects;
2. whether vaccination really decreases the episodes of influenza infection in those coronary artery disease patients who receive the vaccine than those who do not.

Conditions

Interventions

BIOLOGICAL

influenza vaccine

Intramuscular injection of one 0.5-mL dose of influenza vaccine

BIOLOGICAL

placebo for influenza vaccine

Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine

BIOLOGICAL

influenza vaccine

Intramuscular injection of one 0.5-mL dose of influenza vaccine

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Maryam Keshtkar-Jahromi, M.D.; M.P.H. · Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran

  • Hossein Vakili, M.D. · Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran

  • Mohammad Rahnavardi, M.D. · Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran

  • Ali Eskandari, MD · Shaheed Beheshti University (MC)

  • Sharareh Gholamin, MD · Shaheed Beheshti University (MC)

  • Seyed Mostafa Razavi, MD · Shaheed Beheshti University (MC)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607217 on ClinicalTrials.gov